Velcade in Combination Chemo Good Against Mantle Cell Lymphoma

Janssen has applied to the European Medicines Agency (EMA) to expand the label for Velcade (bortezomib) to include treatment of adult patients with previously untreated mantle cell lymphoma.

Specifically, they are seeking approval to add Velcade to frontline therapy for MCL when used in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (VR-CAP).

MCL is a rare, often aggressive, B-cell non-Hodgkin's lymphoma that usually occurs in older adults.

Currently the EMA has licensed Velcade to treat patients with Multiple Myeloma who have not yet had therapy or whose cancer has begun to progress after treatment.

"We are committed to developing and delivering innovative therapeutic solutions to treat serious diseases," said Jane Griffiths, Company Group Chairman, Janssen Europe, the Middle East and Africa (EMEA). "The encouraging data we have seen on VELCADE when used as part of frontline treatment of Mantle Cell Lymphoma reinforce our belief that this therapy has the potential to be an important option in the treatment of this cancer."

Data is derived from the LYM-3002 trial, results of which were presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) and the 19th Annual Congress of the European Hematology Association (EHA). Trial participants were randomized to receive VR-CAP or R-CHOP. VR-CAP was shown to significantly improve progression-free survival (PFS) and showed improvements across other secondary endpoints.

However, VR-CAP was associated with additional toxicity and more serious adverse events than R-CHOP.

Source: MarketwWatch

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap